Death knell sounds for CB1 antagonists
This article was originally published in Scrip
Executive Summary
Anti-obesity drugs that target the cannabinoid 1 receptor look set to be consigned to drug development history after the discontinuation of the two most advanced of these products in this class. Sanofi-Aventis is stopping all clinical trials of Acomplia (rimonabant) following its recent suspension in the EU because of psychiatric safety concerns, and Pfizeris discontinuing its Phase III candidate CP-945,598.